[ACN Newswire] – By Jake KingOncology-focused Celsion Corp. (NASDAQ:CLSN) announced Friday morning that the Phase III HEAT trial met its unblinding milestone, and top-line data will be released in January of 2013, sending … moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Company Begins Data Collection, Expects to Report Top Line Data in January 2013; Reiterates Strong Balance Sheet Position LAWRENCEVILLE, NJ — (Marketwire) — 11/09/12 — Celsion Corporation (NASDAQ: CLSN), … moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LAWRENCEVILLE, NJ — (Marketwire) — 11/06/12 — Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion’s President and Chief … moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LAWRENCEVILLE, NJ — (Marketwire) — 11/02/12 — Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss third quarter … moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboard […]
